The Food and Drug Administration is holding a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections.” The purpose of the public workshop is to discuss the general development considerations of non-traditional therapies, including pre-clinical development, early clinical studies, and phase 3 clinical trial designs to evaluate safety and efficacy.

Presentations by Kevin Outterson, Executive Director of CARB-X, and John Rex, Chief Medical Officer of F2G Ltd.